Diana Rasoulouniriana
Overview
Explore the profile of Diana Rasoulouniriana including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
96
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Farhat-Younis L, Na M, Zarfin A, Khateeb A, Santana-Magal N, Richter A, et al.
Elife
. 2024 Jul;
13.
PMID: 38953289
No abstract available.
2.
Farhat-Younis L, Na M, Zarfin A, Khateeb A, Santana-Magal N, Richter A, et al.
Elife
. 2024 Jun;
12.
PMID: 38885133
Despite the central role of T cells in tumor immunity, attempts to harness their cytotoxic capacity as a therapy have met limited efficacy, partially as a result of the suppressive...
3.
Rasoulouniriana D, Santana-Magal N, Gutwillig A, Farhat-Younis L, Tal L, Amar S, et al.
Cancer Immunol Res
. 2023 Apr;
11(6):792-809.
PMID: 37070661
The pioneering design of chimeric antigen receptor (CAR) T-cell therapy demonstrated the potential of reprogramming the immune system. Nonetheless, T-cell exhaustion, toxicity, and suppressive microenvironments limit their efficacy in solid...
4.
Gutwillig A, Santana-Magal N, Farhat-Younis L, Rasoulouniriana D, Madi A, Luxenburg C, et al.
Elife
. 2022 Sep;
11.
PMID: 36124553
Despite the remarkable successes of cancer immunotherapies, the majority of patients will experience only partial response followed by relapse of resistant tumors. While treatment resistance has frequently been attributed to...
5.
Santana-Magal N, Farhat-Younis L, Gutwillig A, Gleiberman A, Rasoulouniriana D, Tal L, et al.
Cancer Res
. 2020 Mar;
80(10):1942-1956.
PMID: 32127354
The recent success of checkpoint blockade therapies has established immunotherapy as one of the most promising treatments for melanoma. Nonetheless, a complete curative response following immunotherapy is observed only in...
6.
Rasoulouniriana D, Santana-Magal N, Gutwillig A, Farhat-Younis L, Wine Y, Saperia C, et al.
J Clin Invest
. 2019 Aug;
129(10):4151-4164.
PMID: 31449054
While a high frequency of Th1 cells in tumors is associated with improved cancer prognosis, this benefit has been attributed mainly to support of cytotoxic activity of CD8+ T cells....
7.
Santana-Magal N, Rasoulouniriana D, Saperia C, Gutwillig A, Rider P, Engleman E, et al.
J Vis Exp
. 2018 Jun;
(135).
PMID: 29912184
Dendritic cells (DC) are heterogeneous cell populations that differ in their cell membrane markers, migration patterns and distribution, and in their antigen presentation and T cell activation capacities. Since most...
8.
Kramarsky-Winter E, Arotsker L, Rasoulouniriana D, Siboni N, Loya Y, Kushmaro A
Microb Ecol
. 2013 Oct;
67(1):177-85.
PMID: 24141943
Black band disease (BBD), characterized by a black mat or line that migrates across a coral colony leaving behind it a bare skeleton, is a persistent disease affecting massive corals...
9.
Siboni N, Rasoulouniriana D, Ben-Dov E, Kramarsky-Winter E, Sivan A, Loya Y, et al.
J Eukaryot Microbiol
. 2010 Mar;
57(3):236-44.
PMID: 20236189
The surfaces of massive corals of the genus Favia from Eilat, Red Sea, and from Heron Island, Great Barrier Reef, are covered by a layer of eukaryotic microorganisms. These microorganisms...
10.
Rasoulouniriana D, Siboni N, Ben-Dov E, Kramarsky-Winter E, Loya Y, Kushmaro A
Dis Aquat Organ
. 2010 Jan;
87(1-2):91-6.
PMID: 20095244
Black band disease (BBD) is a widespread coral disease which mainly infects massive framework-building corals. BBD is believed to be caused by a consortium of microorganisms and may not result...